Cargando…
The Future of Medicinal Chemistry, PROTAC, and Undruggable Drug Targets
WRD5 is a promising target for anticancer drug discovery. In addition, it plays a vital role in epigenetic regulation. Since biological inactivation of WRD5 is difficult to reach via classical approach, PROTACs (Proteolysis Targeting Chimeras) are offering a new option. In a study, published in this...
Autor principal: | Poso, Antti |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical
Society
2021
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8389887/ https://www.ncbi.nlm.nih.gov/pubmed/34296872 http://dx.doi.org/10.1021/acs.jmedchem.1c01126 |
Ejemplares similares
-
Commentary: PROTACs make undruggable targets druggable: Challenge and opportunity
por: Lu, Bin, et al.
Publicado: (2021) -
Drugging the Undruggable: Advances on RAS Targeting in Cancer
por: Molina-Arcas, Miriam, et al.
Publicado: (2021) -
BRD4 PROTAC degrader ARV-825 inhibits T-cell acute lymphoblastic leukemia by targeting 'Undruggable' Myc-pathway genes
por: Wu, Shuiyan, et al.
Publicado: (2021) -
Drugging an undruggable pocket on KRAS
por: Kessler, Dirk, et al.
Publicado: (2019) -
Therapeutic targeting of “undruggable” MYC
por: Llombart, Victor, et al.
Publicado: (2021)